p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Trial details
- Registry ID
- NCT03268382
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246NCT03268382 | Aprea Therapeutics | Phase 2 | Completed | 2019-07-10Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |